DENMARK

Nov 11, 2026

Hims & Hers stock rebounded 6% to $20 after a 17% plunge, even as five additional states joined the FTC's privacy and billing lawsuit against the company. The initial selloff was triggered by weak Q4 guidance, but bargain hunters appear to be stepping in. Meanwhile, Eli Lilly and Novo Nordisk, key suppliers for Hims & Hers' GLP-1 weight-loss drugs, saw minimal movement, indicating the rebound is specific to Hims & Hers despite its reliance on these suppliers for its growth strategy.

Nov 11, 2026

LiqTech International, Inc. has begun installing its QlariFlow™ ceramic membrane filtration systems at the Worland Aquatic Center in Wyoming, marking its first commercial aquatics installation in the United States. This project, delivered in collaboration with Treatment Specialties, is a significant step in LiqTech's strategy to expand into the U.S. commercial swimming pool market. The QlariFlow system aims to provide high water quality while reducing water, energy, and chemical consumption.

Nov 11, 2026

Genmab's petosemtamab, when combined with Merck's Keytruda, demonstrated a 50% reduction in death risk for head and neck cancer patients during a Phase 3 trial. This breakthrough highlights the growing importance of combination therapies in oncology. The article also touches upon the rise of agrivoltaics and Accenture's managed services business surpassing its consulting arm in revenue.

Nov 10, 2026

Hims & Hers stock plummeted 18% after reporting a surprise GAAP loss in Q3 2026 and cutting its profit outlook for the full year and Q4, missing analyst revenue estimates. The company's gross margin fell due to an increased focus on lower-margin branded GLP-1 weight-loss products and international growth, despite a 13% increase in subscribers year-over-year. Competitors Teladoc and Novo Nordisk experienced much smaller declines, indicating Hims & Hers' selloff was company-specific, while Eli Lilly saw a slight gain.

Nov 10, 2026

LiqTech International, Inc. has announced new Diesel Particulate Filter (DPF) orders, pushing its DPF order backlog to its highest level in years. This growth reflects strong demand in marine and data center applications, with sales exceeding budget throughout 2026 and a 30% increase in sales orders compared to the previous year. The company attributes this success to strengthened direct customer engagement and the expanding applications of its filtration technology.

Nov 10, 2026

Hims & Hers (HIMS) shares fell 18% after the company reported a surprise GAAP loss in Q3 2026 and issued a weaker-than-expected Q4 revenue forecast. The disappointment stems from lower gross margins due to increased sales of lower-margin branded GLP-1 drugs, a cut in the full-year profit outlook, and a decline in net subscribers. Meanwhile, competitors Teladoc (TDOC) and Novo Nordisk (NVO) experienced smaller declines, and Eli Lilly (LLY) saw a slight gain, suggesting the selloff was specific to Hims & Hers.

Nov 10, 2026

GLP-1 drugs like Ozempic and Zepbound are significantly impacting various industries, creating winners such as drugmakers (Eli Lilly, Novo Nordisk) and contract manufacturers, while posing challenges for others. Commercial weight-loss programs like WW International have faced bankruptcy, and packaged food, alcohol, and restaurant sectors are anticipating reduced sales due to decreased appetite among users. The drugs also offer a non-surgical alternative to bariatric surgery and could affect CPAP machine makers, while employers and insurers grapple with the rising costs of coverage.